The World Health Organisation has welcomed the decision of Abbott Laboratories to significantly reduce the price of lopinavir/ritonavir, a second-line antiretroviral therapy to help in the fight against HIV/AIDS.
WHO has reaffirmed its commitment to universal access to HIV prevention services and treatment for people living with HIV/AIDS by 2010.
The World Health Organisation has welcomed the decision of Abbott Laboratories to significantly reduce the price of lopinavir/ritonavir, a second-line antiretroviral therapy to help in the fight against HIV/AIDS.
WHO has reaffirmed its commitment to universal access to HIV prevention services and treatment for people living with HIV/AIDS by 2010.
No comments yet